Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Published Time:
2024-10-23 17:49
Source:
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
Following its inclusion in the 2022 list, Jiangsu Vcare's reappearance in 2024 reflects the industry's full recognition of its innovation strength. Since inception, Jiangsu Vcare has prioritized innovation as its core driver, continuously advancing technological transformation. In recent years, the company has significantly increased R&D investment, recruited top talent, and procured internationally advanced equipment, demonstrating unwavering commitment to innovation.
Jiangsu Vcare has established cutting-edge technology platforms—including AI molecular generation, drug screening, crystal/salt form selection, and novel formulations—focusing precisely on therapeutic areas such as cardiovascular, oncology, inflammation, and autoimmune diseases. Currently, it has5 clinical-stage Class I innovative drug projectsand over10 preclinical projectsunder development, forming a diversified, high-potential R&D pipeline.
Moving forward, Jiangsu Vcare will adhere to its innovation-driven and globalized strategy, targeting frontier technologies and unmet clinical needs to develop breakthrough therapeutics, contributing "Vcare Power" to global health.
Related News
17
2024
/
10
Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA
On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone progress, and the project officially obtained the Investigational New Drug (IND) permission from the US Food and Drug Administration (FDA). This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and is a successful practice of the company's strategies based on original innovation, high-quality standards, and a global layout.
View Details
24
2024
/
09
Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA
At the end of September 2024, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that the US FDA has officially accepted the Investigational New Drug (IND) application of its independently developed new-generation anti-resistant TRK inhibitor VC004. This milestone paves the way for the global commercialization strategy.
View Details
09
2024
/
09
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.
View Details
16
2024
/
08
Jiangsu Vcare Announces Successfully Unblinding of VC005 Topical Gel Clinical Phase I Data
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful unblinding of Phase I clinical data for its self-developed VC005 gel, a second-generation selective JAK1 inhibitor, in the topical treatment of mild-to-moderate atopic dermatitis (AD). The results demonstrated exceptional safety and significant efficacy.
View Details
14
2024
/
08
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced positive topline data from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the oral treatment of moderate-to-severe atopic dermatitis (AD).
View Details
19
2024
/
07
Announcement on Company Name Change by Jiangsu Vcare Pharmatech Co., Ltd.
July 12, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (hereinafter referred to as "the Company") has completed the industrial and commercial registration for its name change and obtained the renewed Business License issued by the Administrative Approval Bureau of Nanjing Jiangbei New Area.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn